Corneal scarring can result in visual disability or blindness. In particular, because the cornea is transparent, a scar severely impacts vision. For scientific discovery of scarring mechanisms, the cornea is a very useful model for studying wound healing, as scarring can be easily evaluated. Corneal stromal wounding induces an influx of myofibroblasts and immune cells into the cornea. The persistence of pathological myofibroblasts and fibroctic matrix forms a scar, blocking transmission of light. Integrin-mediated adhesion promotes myofibroblast differentiation by increasing cell adhesion and cellular tension, required for the assembly of alpha-smooth muscle actin (α-SMA) stress fibers characteristic of myofibroblasts. Integrins also activate latent, matrix-associated endogenous TGFβ by binding to the arginine-glycine-aspartic acid (RGD) domain in its latency-associated peptide. FN-binding integrins (αv and α5β1) in particular are strongly associated with fibrotic outcomes.

Our previous work discovered that the deubiquitinase (DUB) USP10 gene and protein expression were increased in human corneal myofibroblasts. DUBs remove ubiquitin from proteins, preventing degradation. We found that USP10 is a DUB for integrin subunits β1 and β5 but not on β3. (The αv integrin subunit is not directly ubiquitinated but is degraded with the β subunit). Correspondingly, knockdown of USP10 gene expression increased ubiquitination of integrin β1 and β5 subunits, leading to decreased αv/β1/β5 protein levels, whereas gain of USP10 expression increased these protein levels without altering integrin gene expression. As a result of cell-surface integrin accumulation, TGFβ is activated, leading to increased gene expression and organization of the fibroctic markers, α-SMA and fibronectin extra domain A (FN-EDA). Blocking either TGFβ signaling or cell-surface αv integrins after USP10 overexpression prevented or reduced these fibroctic markers, respectively. Furthermore, knockdown of USP10 with USP10-targeting
siRNA after wounding in an ex vivo pig cornea organ culture model and in an in vivo rabbit corneal model significantly reduced the induction of fibrotic markers and promoted regenerative healing. These data suggest that controlling integrin levels via DUB expression is a novel method to control scarring and fibrosis.

Here, we have continued this work by testing if the USP10-mediated increase in integrins on the cell surface after wounding is an undiscovered mechanism for increasing extracellular matrix, a hallmark of scarring and fibrosis. We have focused this study on α5β1 integrin and αv integrins and the matrix molecule, fibronectin. In a stepwise manner, FN secreted by cells is organized to assemble into fibrils (fibrillogenesis). As assembly progresses, short detergent-soluble fibrils are converted into a dense detergent-insoluble fibrillar network. The FN extracellular matrix is a dynamic scaffold that is a central player in cell repair, adhesion, migration, and invasion. The αv integrins, along with the classical FN receptor α5β1 integrin, bind to and coordinate the organization and endocytosis of FN through the binding of FN RGD domains. Using single-cell force microscopy, it was demonstrated that αv integrins bind first to FN, signaling to α5β1 to form additional adhesion sites. This crosstalk strengthens adhesions to FN. Integrins also mediate the endocytosis of FN, but large organized FN fibrils cannot be endocytosed. Membrane-type 1 matrix metalloproteinase (MT1-MMP), a membrane-bound MMP, plays a key role in the extracellular FN cleavage that is necessary for FN endocytosis and subsequent intracellular degradation or recycling back to the cell surface.

Disrupted FN homeostasis leading to a buildup of extracellular FN and, specifically, the fibrotic cellular splice variant, FN-EDA, is linked to the activation of TGFβ and a wide range of disease pathologies, including cardiac, liver, kidney, and dermal fibrosis, as well as glaucoma. Here, we demonstrate that overexpression of the DUB USP10 increases α5β1 and αv integrin recycling to the cell surface. This increase in integrin recycling also promotes endocytosis and subsequent recycling of FN. Together, these data demonstrate that integrin ubiquitination status affects not only the recycling of integrin to the cell surface but also the recycling of integrin-bound matrix.

**Materials and Methods**

**Antibodies and Reagents**

Flag-HA-USP10 (plasmid 22543) for transient overexpression was obtained from Addgene (Watertown, MA, USA). Antibody against α5β1 (volociximab; 2-52680) was obtained from Novus Biologicals (Littleton, CO, USA). The antibody against αv (AV-1b/2b) was produced in the lab of Dr. Sachdev S. Sidhu at the University of Toronto, Ontario, Canada. Fibronectin fluorescein isothiocyanate (FITC; F2733) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Herring sperm DNA (Invitrogen 15634-017) was obtained from Thermo Fisher Scientific (Waltham, MA, USA). Secondary anti-rabbit-488 conjugated antibody (111-545-003) was obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Biotinylated FN (FNR05) was obtained from Cayman Chemical (Ann Arbor, MI, USA). HRP-conjugated streptavidin (61030) was obtained from BioLegend (San Diego, CA, USA). Alexa Fluor 488-conjugated anti-fibronectin antibody (11-0950-01) was obtained from Thermo Fisher Scientific (Waltham, MA, USA). Cell Culture

Human cadaver corneas from unidentified diseased subjects were obtained from the Syracuse Eye Bank (Syracuse, NY, USA) and The Eye-Bank for Sight Restoration (New York, NY, USA). The SUNY Upstate Medical University Institutional Review Board informed us that, as described under Title 45 CFR Part 46 of the Code of Federal Regulations, unidentified cadaver tissue does not constitute research in human subjects. Hence, the experiments performed in this report do not require their approval or waiver. However, all tissue was screened for pathogens as if it were to be transplanted for clinical use in humans. We obtained tissue after the screening process. HCFs were isolated as described previously and maintained in complete media: Invitrogen Dulbecco’s Modified Eagle Medium (DMEM)/Nutrient Mixture F-12 with 10% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA, USA) with Invitrogen ABAM (antibiotic antimycotic) and gentamicin. For experiments, except where noted, cells were plated on 10-μg/mL bovine collagen (Purcol; Advanced BioMatrix, Carlsbad, CA, USA) in supplemented serum-free media (SSFM), comprised of DMEM/F-12 plus RPMI 1640 Vitamin Mix (Sigma-Aldrich); ITS Liquid Media Supplement (Sigma-Aldrich); 1-mg/mL glutathione (Sigma-Aldrich); 2-mM l-glutamine, 1-mM sodium pyruvate, and 0.1-mM non-essential amino acids (Invitrogen); and ABAM and gentamicin (Sigma-Aldrich).

**Live Cell Integrin Recycling Assay**

HCFs (P3 Primary Cell Solution; Lonza Group, Basel, Switzerland) were transfected with 2 μg of control or 2 μg USP10 cDNA and replated in DMEM/F-12 and 1% FBS. Forty-eight hours after transfection, the cells were blockaded with Herring Sperm DNA (10 μg/mL) for 30 minutes. Cells were treated with antibody against α5β1 and αv at 10 μg/mL for 30 minutes. Cells were then stripped (0.2-M acetic acid, 0.5-M NaCl) for 30 seconds and incubated for 90 minutes prior to washing and incubation with Alexa Fluor 488 anti-rabbit antibody for 30 minutes. Live cells were imaged on a LSM 780 confocal microscope (Carl Zeiss, Jena, Germany) and analyzed using the Analyze Particles plugin for ImageJ (National Institutes of Health, Bethesda, MD, USA).

**Biotinylated FN ELISA**

HCFs were transfected (P3 Primary Cell Solution) with 2 μg of control or 2 μg USP10 cDNA and replated in DMEM/F-12 and 1% FBS. Forty-eight hours after transfection, the cells were loaded with 10 μg biotinylated FN for 3 hours. The cells were passaged with trypsin and resuspended in 100 μL of a lysis buffer (50-mM Tris HCL, pH 8.8; 150-mM NaCl; 0.5% Triton X-100) containing protease inhibitor tablets (Roche, Basel, Switzerland) and PMSF (Thermo Fisher Scientific). After centrifugation of the lysates, the supernatant was collected and the pellet was resuspended in 100 μL of the same lysis buffer. After thorough vortexing, the lysates were added together and centrifuged again, and the supernatant was collected. The protocol for the Quantikine ELISA kit (DFBN10; R&D Systems, Minneapolis, MN, USA) was followed. The lysates were diluted in R&D Systems proprietary diluent in a 1:1 ratio. However, the ELISA was modified by using a 1:100 HRP-conjugated streptavidin to detect only biotinylated FN. Signal was detected with an Epoch spectrophotometer (BioTek, Winooski, VT, USA), and samples were analyzed against a standard curve.
Fixed Cell FN-FITC Recycling Assay

HCFs were plated on glass coverslips and treated with FN-FITC (F273; Sigma-Aldrich) for 3 hours in DMEM/F-12 and 1% FBS. One group was fixed with 3% paraformaldehyde (Thermo Fisher Scientific) in PBS and imaged. The remaining cells were passaged with trypsin; replated; fixed in 3% paraformaldehyde; and imaged at 2, 18, 26, and 72 hours after passage on an ECLIPSE Ni microscope (Nikon, Tokyo, Japan) (Fig. 2A).

Flow Cytometry

HCFs (200,000) were plated in DMEM/F-12 and 1% FBS. The next day, cells were treated with 4 μg/mL of FN-FITC for 3 hours. The cells were then washed with Gibco PBS (Thermo Fisher Scientific), detached with trypsin (Corning, Manassas, VA, USA) and collected in DMEM/F-12 with 1% FBS. The cells were counted and centrifuged at 100g for 5 minutes, washed with PBS, and pelleted again. The cell pellet was resuspended in PBS plus 1% BSA with and without 2 mg/mL of Trypan Blue and analyzed by flow cytometry (BD LSRFortessa; BD Biosciences, Franklin Lakes, NJ, USA). Data analysis was performed in FlowJo 10.7.2 (Fig. 2B). HCFs (1,000,000) were transfected with 2 μg control FLAG and USP10 FLAG cDNA (Sigma-Aldrich). After 48 hours, cells were detached with TrypLE Express (12605028; Thermo Fisher Scientific), washed at 3000 rpm for 2 minutes, and resuspended in FACs buffer. The cells were stained with live/dead stain (LIVE/DEAD Fixable Violet Dead Cell Stain Kit, L34965; Thermo Fisher Scientific) and fixed with 3% paraformaldehyde. Next, the cells were permeabilized with 0.2% saponin containing FACS buffer and stained with anti-FLAG antibody (9A3, 8146S; Cell Signaling Technology, Danvers, MA, USA), followed by Alexa Fluor 647 AffiniPure Goat Anti-Mouse IgG (H+L) (115-605-003; Jackson ImmunoResearch, West Grove, PA, USA). The cells were then washed and resuspended in FACs buffer and analyzed using a BD LSR II flow cytometer. Data analysis was performed in FlowJo 10.7.2 (Supplementary Fig. S2).

Live Cell Biotinylated FN Recycling Assay

HCFs were transfected (P3 Primary Cell Solution) with 2 μg of control or USP10 cDNA and replated in DMEM/F-12 and 1% FBS. Twenty-four hours after transfection, the cells were loaded with 10 μg biotinylated FN for 3 hours. Cells were then passaged and replated on a 24-well glass-bottom plate (1812-024; Chemglass, Vineland, NJ, USA). After 48 hours, cells were treated separately with a streptavidin-488 or a FN-EDA-488 (Santa Cruz) antibody to avoid any differences in quantification of fluorophore. Images were captured on a Zeiss LSM 780 confocal microscope and analyzed using the 3D Object Counter plugin for ImageJ.

Live Cell Assay: Percentage of FN-EDA Versus Recycled Biotinylated FN

Cells were transfected with 2 μg of control or USP10 cDNA and replated in DMEM/F-12 and 1% FBS. Twenty-four hours after transfection, the cells were loaded with 10 μg biotinylated FN for 3 hours. Cells were then passaged and replated on a 24-well glass-bottom plate (1812-024; Chemglass, Vineland, NJ, USA). After 48 hours, cells were treated separately with a streptavidin-488 or a FN-EDA-488 (Santa Cruz) antibody to avoid any differences in quantification of fluorophore. Images were captured on a Zeiss LSM 780 confocal microscope and analyzed using the 3D Object Counter plugin for ImageJ.

Image Quantification

Live cell images were captured using a Zeiss LSM 780 confocal microscope with a 40× oil immersion objective. Each image was taken at 212.55 × 212.55 mm (2636 × 2636 pixels) and analyzed using ImageJ. For integrin recycling (Fig. 1), the Analyze Particles plugin for ImageJ was used to threshold the images and measure the percent area of fluorescence of the image. For fibronectin recycling and secreted FN (Figs. 3–5), the 3D Object Counter plugin for ImageJ was used to threshold images and quantify puncta (above 0.01 mm in size).

Statistical Analysis

Graphical data are the mean ± SEM of at least three technical repeats using two different patient-derived cell lines. Statistical significance for analysis of these images was calculated using a Student's t-test, one-way ANOVA, and Tukey's multiple comparisons test or two-way ANOVA and Fisher's test.

RESULTS

USP10 Overexpression Increases Integrin Recycling and FN Endocytosis

Previously, we demonstrated by cell surface biotinylation that integrins αv, β1, and β3 accumulate on the cell surface of HCFs in response to USP10 overexpression. This resulted from post-translational removal of ubiquitin from integrins. Although it is assumed that reduced degradation in response to less ubiquitination and accumulation on the cell surface indicates that USP10 overexpression promotes integrin recycling instead of degradation, to prove this we subjected HCFs to a live cell confocal integrin recycling assay.

HCFs were transfected with either control or USP10 cDNA and incubated for 48 hours. To quantify αv/51 and αv recycling to the cell surface, cells were treated with either anti-αv/51 or anti-αv antibody for 30 minutes at 37°C prior to cell surface stripping with low-pH buffer and another 30-minute incubation at 37°C to allow for recycling of integrins.

Live Cell αv and α5β1 Blocking Antibody FN Recycling Experiment

HCFs were transfected (P3 Primary Cell Solution) with 2 μg of control or USP10 cDNA and replated in DMEM/F-12 and 1% FBS. Twenty-four hours after transfection, the cells were treated with 10 μg/mL αv and α5β1 blocking anti-
bound to their respective antibodies. Signal was quantified by detection with secondary antibody-488 and imaged by live cell confocal microscopy so that only external (recycled) integrins were imaged and quantified. We found that USP10 overexpression increased $\alpha_5\beta_1$ integrin recycling by 1.9-fold ($P < 0.001$), and $\alpha_v$ integrin recycling by 1.7-fold ($P < 0.01$) (Figs. 1A–1F) as quantified by total fluorescence intensity (see Materials and Methods). We used these same images to analyze cell area. We found that USP10 overexpression increased cell area by 1.52-fold ($P < 0.01$) (Supplementary Fig. S1). We reasoned, however, that the cells were not larger, but that they appeared larger on a two-dimensional surface because of the augmented cell-surface integrin levels and improved cell attachment producing a flatter and larger cell compared with control. To directly test if USP10 overexpression increases cell size in solution, we performed flow cytometry comparing control vector-FLAG transduced cells compared to USP10-FLAG overexpressing cells. We found no difference in the size of the USP10 overexpressing cells compared with control (Supplementary Fig. S2). Furthermore, the fact that biochemical endpoints that are equalized by protein, not microscopic images (western blots and immunoprecipitation of cell-surface integrins), demonstrate a more than two-fold difference in cell-surface integrin accumulation and FN internalization by ELISA (see below) when USP10 is overexpressed supports the idea that USP10 increases cell-surface integrin expression, not simply larger cells.

Because cell-surface integrin expression is increased in USP10 overexpressing cells, and FN is endocytosed via integrins, we next asked if USP10 overexpression increased uptake of FN. HCFs were transfected with USP10 or control cDNA. After 48 hours, cells were loaded with biotinylated FN for 3 hours prior to cell detachment with trypsin and lysing. Samples were equalized by protein concentration. A FN ELISA was used to quantify intracellular biotinylated FN. USP10 overexpressing cells increased FN uptake by 2.2-fold ($P < 0.05$) (Fig. 1G).

Establishing a FN Recycling Assay

We used FN-FITC to test conditions and time points for a FN recycling assay. Although FN recycling assays have been established, our ultimate goal was a quantitative live cell imaging approach. First, to establish the parameters of FN fibril formation, HCFs were incubated for 3 hours with soluble FN-FITC and then fixed and imaged (pre-passage). The remainder of the cells were detached with trypsin, replated, and imaged at 2, 18, 36, and 72 hours post-passage to determine if internalized FN would re-emerge and organize fibrils (Fig. 2A). We found that plating cells in media containing at least 1% FBS was required to produce consistent fibril

![Figure 1](image-url)
Extracellular FN was removed by trypsinization. (A) To determine if soluble FN would form fibrils in our assay conditions, HCFs were loaded with FN-FITC for 90 minutes. Cells were imaged immediately or were passaged with trypsin and then replated and imaged at the corresponding time points. (B) Flow cytometry was utilized to determine if cell passaging was sufficient to remove extracellular FN. HCFs were loaded with FN-FITC for 90 minutes. (Top row) Untreated cells compared with FN-FITC treated cells and overlay. (Bottom row) Extracellular fluorescence was quenched with Trypan Blue. FN-FITC–treated cells compared with the FN-FITC + Trypan Blue (TB)–treated cells and overlay. Two primary cell lines (total N = 3 repeats).

HCFs were incubated without FN-FITC (control) or with FN-FITC for 3 hours prior to trypsinization. Pelleted cells were subjected to flow cytometry. The data in the top row of Figure 2B demonstrate that, compared to control, the FN-FITC–treated cells had an increased signal, and cells were shifted to the right. In the second set of experiments, FN-FITC–treated cells were trypsinized, pelleted, and treated with or without Trypan Blue. Trypan Blue masks the FITC extracellular signal. FN-FITC–treated cells compared with FN-FITC–treated cells with Trypan Blue presented with identical profiles, demonstrating that the FITC signal is intracellular and that, as expected, the trypsin had removed extracellular FN-FITC (Fig. 2B, bottom row). Together these data suggest that internalized FN can produce extracellular fibrils in the time frame tested and that trypsin can reliably remove extracellular FN.

USP10 Overexpression Increases Extracellular FN Expression and Organization

Using the parameters discovered in the above assays, we utilized soluble biotinylated FN and live cell imaging to detect extracellular fibrillar biotinylated FN. HCFs were transfected with either control or USP10 cDNA. After 24 hours, cells were loaded for 3 hours with biotinylated FN, trypsinized, and replated for live cell imaging. At days 1 to 4 after reseeding, biotinylated FN was detected with streptavidin-488. Because the cells were neither fixed nor permeabilized, only the extracellular biotinylated FN was...
FIGURE 3. USP10 overexpression increased FN recycling. For the live cell FN recycling assay, HCFs were transfected with 2 μg control or USP10 cDNA. Twenty-four hours after transfection, HCFs were loaded with biotinylated FN for 3 hours. After trypsinization, cells were replated for days 1 to 4. FN recycling was detected with streptavidin-488 by live cell confocal microscopy. (A) Images from days 1 to 4. Scale bar: 50 μm. (B) Quantification of puncta count; USP10 overexpressing cells increased FN recycling (1.7–2.2-fold). Two-way ANOVA, two primary cell lines, total N = 6 repeats, five images per condition/per experiment. One dot represents the average of quantification of images in one experiment. (C) Average number of cells quantified per image were similar; Student’s t-test.

FIGURE 4. Blocking integrins reduced FN recycling. (A–C) Live cell FN recycling assay. HCFs were transfected with 2 μg USP10 cDNA for 24 hours prior to treatment with control IgG, α5β1 integrin-blocking antibody, or αv integrin-blocking antibody. After 1 hour with antibodies, cells were treated with biotinylated FN for 3 hours prior to trypsinization and replating for 2 days. Scale bar: 50 μm. (D) Quantification. USP10 overexpressing cells treated with control IgG compared with α5β1 blocking antibody reduced FN recycling by 62% (P < 0.05), and IgG compared with αv blocking antibody reduced FN recycling by 84% (P < 0.05). One-way ANOVA, two primary cell lines, total N = 4 repeats, five images per condition/per experiment were analyzed.
FIGURE 5. Ratio of total versus recycled FN for live cell FN recycling/secrection assay. (A–D) HCFs were transfected with 2 μg control or USP10 cDNA. Twenty-four hours after transfection HCFs were loaded with biotinylated FN for 3 hours. After trypsinization, cells were replated for 2 days. (A, C) FN recycling was detected with streptavidin-488 by live cell confocal microscopy. (B, D) Secreted FN-EDA was detected with FN-EDA-488 (colored red for image). Scale bars: 50 μm. (E) Quantification of recycled FN in control cells compared with USP10 overexpressing cells (1.79-fold; *p < 0.05). Quantification of secreted FN-EDA in control cells compared with USP10 overexpressing cells (2.18-fold; *p < 0.05). (F) The percentage of recycled FN and secreted FN-EDA for control cells versus USP10 overexpressing cells was not significantly different. One-way ANOVA, two primary cell lines, total N = 4 repeats, five images per condition/per experiment were analyzed.

detected. In Figure 3A shows representative images from days 1 to 4 after reseeding of cells. Images were quantified by puncta count (see Materials and Methods). Using two-way ANOVA, the data from six independent experiments demonstrate that overexpression of USP10 resulted in a (1.7–2.2-fold; *p < 0.05) increase in extracellular recycled biotinylated FN over a 4-day period (Fig. 3B). The average number of cells in each frame analyzed was not significantly different between conditions (Fig. 3C). To test if USP10 affected total cell number, in separate experiments from the recycling assays cells were counted after transfection from days 1 to 4. In Supplementary Figure S3, we demonstrate that the USP10 cDNA did slightly impact cell viability, although it was not statistically significant. However, comparing the growth rate of cells in each group, USP10 overexpressing cells had a slightly higher growth rate over the 4 days, likely to overcome the cell loss after transfection, but again not statistically significant. These controls demonstrate that the USP10-mediated increase in recycled FN is not derived from a significant overall increase in cell number.
Blocking Integrons Significantly Reduces FN Recycling

To prove that integrins are involved in the recycling of FN, the recycling assay with control or USP10 cDNA was performed as above. Twenty-four hours after transfection, blocking antibodies to either α5β1 or αv integrin were added 1 hour prior to treatment with biotinylated FN for 3 hours. Cells were trypsinized, reseeded, and analyzed 48 hours later (Fig. 3, day 2). Figure 4 demonstrates a 62% decrease ($P < 0.05$) in FN recycling with α5β1-blocking antibody and an 84% decrease ($P < 0.05$) with αv-blocking antibody compared with IgG control. Cell detachment was not observed with any of the antibodies in the timeframe of the assay. These data demonstrate that, as expected, FN receptor integrins are involved in FN recycling.

Recycled FN Accounts for Approximately One-Third of Total FN in HCFs

To ascertain the contribution of recycled biotinylated FN compared with cellular FN-EDA, we again overexpressed control or USP10 cDNA in HCFs. After 24 hours, cells were loaded with biotinylated FN for 3 hours and then reseeded for another 48 hours (Fig. 3, day 2). Imaging of biotinylated FN with streptavidin-488 was performed on one set of coverslips and compared with cells from the same experiment treated with anti–FN-EDA-488 antibody. Both were imaged by live cell confocal microscopy. Quantifying the recycled FN and FN-EDA separately but each with a 488 fluorophore eliminated any variance between fluorophores during quantification. Representative images from each condition are shown in Figures 5A to 5D. FN-EDA expression is colored red to easily distinguish recycled from endogenously secreted FN. Image analysis is shown in Figure 5E. When control cDNA was compared with USP10 cDNA for recycled FN (Figs. 5A, 5C), we found a 1.8-fold increase in USP10-mediated recycling ($P < 0.05$) (Fig. 5). When control cDNA was compared to USP10 cDNA for extracellular FN-EDA (Figs. 5B, 5D), a 2.1-fold increase in USP10-mediated FN-EDA synthesis and extracellular organization was quantified ($P < 0.0001$). We then calculated the percentage of recycled FN versus secreted FN-EDA in each condition and found that, in HCFs transfected with control cDNA, recycled FN accounted for 34% ± 7% of total and FN-EDA 66% ± 4% of total. Similarly, with USP10 overexpression, recycled FN accounted for 29% ± 5% of total and endogenously secreted FN-EDA 71% ± 9% of total. These percentages are represented in Figure 5F. Interestingly, even though USP10 increased both recycled FN and secreted FN-EDA and therefore the total FN, the relative ratios of recycled and FN-EDA between control and USP10 cDNA were not significantly different.

**Discussion**

Our previous work on USP10 established that USP10 gene expression is upregulated upon wounding and that USP10 removes ubiquitin from substrate integrins, reducing integrin degradation and initiating an increase in cell-surface integrin accumulation that promotes scarring. Further, the subsequent cell-surface integrin-mediated activation of TGFβ induces the myofibroblast phenotype and a significant increase in FN-EDA gene and protein expression and organization, as determined by quantitative PCR, microscopy, and western blot. These results were bolstered by our recent studies demonstrating that knockdown of USP10 after wounding, ex vivo in porcine cornea and in vivo in rabbit corneas, significantly reduced scarring. Because integrins are endocytosed with matrix, here we extended our previous studies by testing if reduced intracellular degradation of integrins as a result of USP10 overexpression (USP10 removes ubiquitin, integrins accumulate) would also result in USP10-driven matrix accumulation if integrin/ECM were recycled back to the cell surface together. We focused on integrins α5β1 and αv and the matrix molecule FN, which undergoes a stepwise integrin-dependent polymerization to generate fibrils from soluble, monomeric FN. The α5β1 and αv integrins recognize the common integrin-binding motif (RGD) in FN and coordinate to achieve efficient FN binding.

We found that USP10 overexpression increased αv and α5β1 integrin recycling, FN uptake, and FN recycling (Figs. 1–4). Furthermore, FN-EDA secretion was also significantly increased, as previously reported to result from elevated USP10-induced integrin-mediated TGFβ activity. We found here that the relative contributions of endogenously secreted FN-EDA compared with recycled FN were approximately 2/3 to 1/3 of total FN, respectively (Fig. 5). An overview of these USP10-mediated integrin/FN findings are diagrammed in Figure 6.

Our recycling and secretion experiments were performed in media containing 1% serum, which we found was necessary to generate observable fibril formation in the timeframe of 1 to 4 days. We cannot totally discount the possible contribution of serum-derived FN-EDA to the FN matrix that we detected as endogenously secreted FN (Fig. 5, red) or the contribution of serum-containing factors to the stimulation of endogenous synthesis of FN-EDA. However, overall, FN in serum is largely plasma FN and not cellular FN (FN-EDA), and plasma FN will not be detected with the FN-EDA–specific antibody. Also, importantly, as one would expect, the same media were used in both control and USP10 overexpressing cells. Thus, any cross-reactivity of the anti–FN-EDA antibody to FN or serum-derived growth factor–mediated stimulation of FN-EDA would be detected equally in both control and USP10 overexpressing cells. Furthermore, the finding that in 1% serum-containing media we still observed a greater than two-fold increase in endogenously secreted FN-EDA in USP10 overexpressing cells (similar to our data in serum-free media) suggests that the 1% serum-containing media did not obscure results. In addition, we used a 488 fluorophore to detect both recycled and secreted FN on cells from the same transfection experiment but in parallel, instead of double labeling with two different fluorophores. We did this to eliminate any differences in quantification between two different fluorophores. The secreted FN-EDA was assigned a red color in Figure 5 to differentiate between the two FNs. Together, our data support a largely unappreciated contribution of integrin-mediated recycled FN to the accumulation of ECM in fibrosis. Furthermore, the deubiquitinase USP10 modulates integrin/FN recycling and cell surface accumulation.

Mechanistically, endocytosis of FN is linked to fibrotic phenotypes. Fibrillar FN is cleaved by MT1-MMP, endocytosed in an integrin and caveolin-1–dependent manner, and degraded in the lysosome. A previous study demonstrated that α5β1 binding to FN was necessary for ubiquitination of α5 and degradation of the internalized α5β1/FN complex in the endosomal pathway. Furthermore,
The authors proposed that reduced degradation of integrins would instead induce recycling of the complex to the cell surface to form dysfunctional adhesion sites yielding pathological cell adhesion and a buildup of ECM. In support of this idea, a recent study found that, in response to exogenous TGFβ treatment, endocytosed FN favored recycling through a rab11 pathway back to the cell surface over intracellular degradation, with a requirement for TGFβRII binding to α5β1.30 Similarly, we found that USP10 overexpression (which induces TGFβ activity)4 increased integrin recycling (Figs. 1A–1F), FN endocytosis (Fig. 1G), and FN recycling (Fig. 3).

The connection between DUBs and fibrosis is a burgeoning field.50 The DUB ubiquitin C-terminal hydrolase L1 (UCH-L1) is suggested to play a role in liver fibrosis, as knockdown of UCH-L1 blocks progression of CCl4-induced fibrosis in mice, and a specific UCH-L1 inhibitor blocks fibrosis in a cellular idiopathic pulmonary fibrosis model.51,52 DUBs also have been found to directly regulate TGFβ signaling. UCH-L5 stabilizes SMAD2/3, and USP11 stabilizes TGFβ receptor TβRII, promoting TGFβ1 signaling. Both DUBs were also increased in patients with idiopathic pulmonary fibrosis and bleomycin-challenged mice.53,54 Furthermore, pan-inhibition of DUBs with the DUB inhibitor PR-619 ameliorates renal fibrosis through the SMAD4 pathway.55 Finally, in a model of diabetic renal fibrosis, the DUB ubiquitin-specific peptidase 9 X-linked (USP9X) is protective, attenuating advanced glycation-end products and subsequent fibrotic markers.56

In terms of the biological and pathological importance of cellular FN-EDA, studies have linked this splice variant to the generation of fibrotic outcomes in many tissues.57,58 FN-EDA expression is downstream of PI3K/AKT signaling.59,60 There are several pathways of AKT activation leading to subsequent FN-EDA expression. β1-integrin activation leads to the phosphorylation of focal adhesion kinase (FAK) on Tyr-397 and in turn, PI3K and AKT activation.61 Other studies have shown that TGFβ can activate FAK through a Smad3 pathway or activate PI3K/AKT through a p38 pathway.60 Regardless of the upstream events, AKT activation leads to FN-EDA expression and myofibroblast persistence.59,60 Recently, it was discovered that FN-EDA binds preferentially to the latent TGFβ protein binding protein 1 (LTBP-1), and blocking this interaction results in reduced local TGFβ activity.32 Supporting the idea that FN-EDA is critical to TGFβ signaling is the finding that FN-EDA null mice display dysfunctional healing but are protected against bleomycin-induced lung fibrosis.38,62,63 In addition, lung cancer cellsecreted FN-EDA binds to monocytes driving proinflammatory responses in the tumor microenvironment via the nuclear factor-κB (NF-κB) pathway, and circulating FN-EDA was found to be a biomarker for endothelial cell activation and inflammation in diabetes.64–66 Because of the importance of matrix to disease and pathologies, it is thought that standard therapies are in part effective because of their secondary effect on ECM. New therapies are directly targeting ECM, and ECM ligands are also being used as drug delivery mechanisms.67–70 Because integrin/ECM binding and accumulation play a central role in pathological myofibroblast persistence, USP10 may be an important new target for anti-scarring therapy. Overall, our work demonstrates that DUB-mediated intracellular control of integrin trafficking is a novel method to regulate cell surface accumulation of recycled integrins with their corresponding ECM.

Acknowledgments

Supported by grants from the National Eye Institute, National Institutes of Health (R01 EY024942, R01 EY030567), US Department of Veteran’s Affairs Biomedical Laboratory Research and Development Service Merit Review Award (101 BX005360), SUNY Upstate Start-Up Funds, unrestricted grant to the Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness and Lions Club District 20-Y (AMB), Charles H. Best foundation fellowship (EG), an operating grant from the
Canadian Institutes of Health Research (MOP-136944), and an operating grant from Bristol-Myers Squibb (SSS).

Disclosure: A.T. Phillips, None; E.F. Bounil, None; N. Castro, None; A. Venkatesan, None; E. Gallo, None; J.J. Adams, None; S.S. Sidhu, None; A.M. Bernstein, None

References


